Joan Gilmore

1.7k total citations
16 papers, 766 citations indexed

About

Joan Gilmore is a scholar working on Oncology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Joan Gilmore has authored 16 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Genetics and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Joan Gilmore's work include CAR-T cell therapy research (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Lymphoblastic Leukemia research (2 papers). Joan Gilmore is often cited by papers focused on CAR-T cell therapy research (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Lymphoblastic Leukemia research (2 papers). Joan Gilmore collaborates with scholars based in United States and Germany. Joan Gilmore's co-authors include Thomas P. Cappola, Mary Putt, Michael S. Parmacek, Jonathan A. Epstein, Sridhar Hannenhalli, Edward E. Morrisey, Kenneth B. Margulies, Junwen Wang, Carl H. June and Bruce L. Levine and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Joan Gilmore

16 papers receiving 748 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joan Gilmore United States 12 322 319 167 114 96 16 766
Xiaohu Fan Canada 13 223 0.7× 87 0.3× 113 0.7× 53 0.5× 82 0.9× 18 596
Barry Fine United States 11 389 1.2× 97 0.3× 94 0.6× 21 0.2× 42 0.4× 26 686
Africa F. Wallace United States 8 195 0.6× 156 0.5× 59 0.4× 34 0.3× 265 2.8× 13 650
Ken Sin Lo Canada 12 400 1.2× 280 0.9× 107 0.6× 134 1.2× 121 1.3× 20 745
Ashish Yeri United States 20 721 2.2× 91 0.3× 238 1.4× 54 0.5× 77 0.8× 32 1.1k
Marco De Giorgi Italy 15 482 1.5× 93 0.3× 139 0.8× 172 1.5× 62 0.6× 54 945
Rachel N. Steinmetz United States 9 189 0.6× 398 1.2× 29 0.2× 118 1.0× 120 1.3× 17 590
Lianghui Zhang United States 13 482 1.5× 57 0.2× 119 0.7× 29 0.3× 115 1.2× 20 794
Junedh Amrute United States 11 250 0.8× 57 0.2× 190 1.1× 14 0.1× 107 1.1× 27 532
Rafet Başar United States 14 118 0.4× 248 0.8× 31 0.2× 35 0.3× 240 2.5× 25 465

Countries citing papers authored by Joan Gilmore

Since Specialization
Citations

This map shows the geographic impact of Joan Gilmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Gilmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Gilmore more than expected).

Fields of papers citing papers by Joan Gilmore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Gilmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Gilmore. The network helps show where Joan Gilmore may publish in the future.

Co-authorship network of co-authors of Joan Gilmore

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Gilmore. A scholar is included among the top collaborators of Joan Gilmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Gilmore. Joan Gilmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Narayan, Vivek, Julie S. Barber-Rotenberg, Joseph A. Fraietta, et al.. (2021). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 125–125. 14 indexed citations
2.
Narayan, Vivek, Whitney L. Gladney, Gabriela Plesa, et al.. (2020). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). TPS269–TPS269. 20 indexed citations
3.
Uy, Natalie, Edward Pequignot, Noelle V. Frey, et al.. (2020). Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood. 136(Supplement 1). 30–32. 7 indexed citations
4.
Chong, Elise A., James N. Gerson, Daniel J. Landsburg, et al.. (2019). Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications. Blood. 134(Supplement_1). 594–594. 10 indexed citations
5.
Narayan, Vivek, Whitney L. Gladney, Gabriela Plesa, et al.. (2019). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). TPS347–TPS347. 25 indexed citations
6.
Frey, Noelle V., Pamela A. Shaw, Elizabeth O. Hexner, et al.. (2019). Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 38(5). 415–422. 173 indexed citations
7.
Porter, David L., Norbert Frey, Jan J. Melenhorst, et al.. (2016). Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.. Journal of Clinical Oncology. 34(15_suppl). 3009–3009. 28 indexed citations
8.
Porter, David L., Michael Kalos, Norbert Frey, et al.. (2013). Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. Blood. 122(21). 4162–4162. 22 indexed citations
9.
Porter, David L., Norbert Frey, Alison W. Loren, et al.. (2013). A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). TPS7132–TPS7132. 2 indexed citations
10.
Porter, David L., Michael Kalos, Norbert Frey, et al.. (2013). Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. Blood. 122(21). 873–873. 17 indexed citations
11.
Porter, David L., Stephan A. Grupp, Michael Kalos, et al.. (2012). Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. Blood. 120(21). 717–717. 16 indexed citations
12.
Cappola, Thomas P., Mingyao Li, Jing He, et al.. (2010). Common Variants in HSPB7 and FRMD4B Associated With Advanced Heart Failure. Circulation Cardiovascular Genetics. 3(2). 147–154. 84 indexed citations
13.
Cappola, Thomas P., Mingyao Li, Jing He, et al.. (2008). Abstract 4874: Large-Scale Candidate Gene Association with Human Heart Failure. Circulation. 118(suppl_18). 1 indexed citations
14.
Hannenhalli, Sridhar, Mary Putt, Joan Gilmore, et al.. (2006). Transcriptional Genomics Associates FOX Transcription Factors With Human Heart Failure. Circulation. 114(12). 1269–1276. 191 indexed citations
15.
Horwitz, Phillip A., Emily J. Tsai, Mary Putt, et al.. (2004). Detection of Cardiac Allograft Rejection and Response to Immunosuppressive Therapy With Peripheral Blood Gene Expression. Circulation. 110(25). 3815–3821. 113 indexed citations
16.
Buono, Russell J., Thomas N. Ferraro, Michael J. O’Connor, et al.. (2001). Lack of Association Between an Interleukin 1 Beta (IL‐1β) Gene Variation and Refractory Temporal Lobe Epilepsy. Epilepsia. 42(6). 782–784. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaohu Fan Breakdown of academic impact, for papers by Barry Fine Breakdown of academic impact, for papers by Africa F. Wallace Breakdown of academic impact, for papers by Ken Sin Lo Breakdown of academic impact, for papers by Ashish Yeri Breakdown of academic impact, for papers by Marco De Giorgi Breakdown of academic impact, for papers by Rachel N. Steinmetz Breakdown of academic impact, for papers by Lianghui Zhang Breakdown of academic impact, for papers by Junedh Amrute Breakdown of academic impact, for papers by Rafet Başar
Rankless by CCL
2026